Response to a 6-month personalized dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease
N. Perez-Diaz-del-Campo,G. Castelnuovo,C. Rosso,G.P. Caviglia,E. Dileo,M. Guariglia,A. Armandi,I. Poggiolini,F. Saba,A. Olivero,M.L. Abate,G.M. Saracco,F. Bioletto,S. Bo,E. Bugianesi
DOI: https://doi.org/10.1016/j.dld.2024.01.094
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction and aim Lifestyle modification with weight loss is so far the cornerstone of approaches to metabolic dysfunction-associated steatotic liver disease (MASLD); however, it has been shown that each individual's response to diet may differ depending on their background. In this study, we aimed to study the impact of a 6-month dietary intervention on the improvement of liver steatosis in patients with MASLD. Methods 87 patients with MASLD were randomly assigned to one of the three dietary arms: low-carbohydrate diet, Mediterranean diet and control diet. Subjects were evaluated at baseline and after 6 months. PNPLA3-rs738409 SNP was genotyped in all patients. Liver steatosis was evaluated by Controlled Attenuation Parameter (CAP)(Fibroscan®530, Echosens). Results Overall, median age was 51 years (IQR 42;61), 69% of patients were male and 17% diabetic. Weight, systolic and diastolic blood pressure significantly decreased after the intervention (P<0.001, P=0.003 and P=0.017, respectively), as well as hepatic transaminases (AST, P=0.002, ALT P<0.001 and GGT P=0.014), CAP, glucose and insulin levels (P<0.001, P=0.005, P=0.005, respectively). 23 patients decreased ≥ 15% their CAP values after the 6-month intervention, showing a significant improvement in weight (P<0.001), waist circumference (P=0.003), systolic blood pressure (P<0.001) and GGT (P=0.030). Furthermore, a logistic regression adjusted by weight-loss, sex, PNPLA3-rs738409 and diet showed that weight-loss was significant and independently associated with the improvement of CAP, while a trend for CG/GG PNPLA3-rs738409 towards improved steatosis was observed. Conclusion Weight loss and carrying the CG/GG PNPLA3-rs738409 genotype appear to be significant factors in the improvement of hepatic steatosis in patients with MASLD. However, more studies considering the individual response to nutritional treatment are needed to accurately understand precision nutrition. This research has been supported by the University of Torino, grant number ROSC_RILO_21_01.
gastroenterology & hepatology